10 February 2025

LungLife AI, Inc.

(the "Company" or "LungLife")

Change of Nominated Adviser and Joint Broker

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the appointment of Allenby Capital Limited as the Company's Nominated Adviser and Joint Broker with immediate effect, alongside the Company's existing Joint broker, Goodbody.

AIM Rule 17 Schedule Two (g) information:

The Company also provides the following information relating to directors' disclosure under Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for Companies:

LungLife's Chairman, Gordon Davis, was a director of C-Quential Limited until his resignation on 28 February 2001.  C-Quential Limited entered into a creditors voluntary liquidation on 11 February 2002 and was subsequently dissolved on 18 August 2007.

For further information please contact:

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.